Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization

Pathological cardiac hypertrophy is characterized by a shift in metabolic substrate utilization from fatty acids to glucose, but the molecular events underlying the metabolic remodeling remain poorly understood. Here, we investigated the role of liver X receptors (LXRs), which are key regulators of glucose and lipid metabolism, in cardiac hypertrophic pathogenesis. Using a transgenic approach in mice, we show that overexpression of LXRα acts to protect the heart against hypertrophy, fibrosis, and dysfunction. Gene expression profiling studies revealed that genes regulating metabolic pathways were differentially expressed in hearts with elevated LXRα. Functionally, LXRα overexpression in isolated cardiomyocytes and murine hearts markedly enhanced the capacity for myocardial glucose uptake following hypertrophic stress. Conversely, this adaptive response was diminished in LXRα-deficient mice. Transcriptional changes induced by LXRα overexpression promoted energy-independent utilization of glucose via the hexosamine biosynthesis pathway, resulting in O-GlcNAc modification of GATA4 and Mef2c and the induction of cytoprotective natriuretic peptide expression. Our results identify LXRα as a key cardiac transcriptional regulator that helps orchestrate an adaptive metabolic response to chronic cardiac stress, and suggest that modulating LXRα may provide a unique opportunity for intervening in myocyte metabolism.


Introduction
Pathological cardiac hypertrophy and remodeling ensue in response to sustained elevations in hemodynamic workload (Frey & Olson, 2003). A hallmark of this remodeling process is the alteration in myocardial energy metabolism which is necessitated by increased energy demand (Neubauer, 2007;Ventura-Clapier et al, 2011). Under normal physiological conditions, the heart predominantly consumes fatty acids (FA), whereas various stressors trigger a compensatory shift toward glucose, the preferred substrate for its oxygen-sparing effect in ATP production (Stanley et al, 2005;Opie & Knuuti, 2009). Despite the success of current pharmacological strategies which aim to reduce afterload and hypertrophic growth using beta blockers and inhibitors of the renin-angiotensin-aldosterone system, heart failure nevertheless remains a progressive disease with high morbidity and mortality. Interventions in metabolic remodeling therefore represent a promising therapeutic adjunctive for targeting pathological cardiac hypertrophy and development of heart failure (Ardehali et al, 2012). Liver X receptors (LXRs) are nuclear receptors that have emerged as central metabolic regulators in various organ systems and cell types. At the molecular level, LXRs function as ligand-activated transcription factors that intricately regulate and coordinate cholesterol homeostasis, glucose and lipid metabolism, and inflammatory signaling. As such, the importance of LXRs in the cardiovascular system is mainly attributed to their atheroprotective effects in accelerating reverse cholesterol transport (Naik et al, 2006;Zhang et al, 2012), and reducing atherosclerotic lesion size and inflammation (Schuster et al, 2002;Joseph et al, 2003;Giannarelli et al, 2012). The biological functions of LXRs are mediated via two subtypes, LXRa (NR1H3), which is predominantly expressed in liver, adipose, intestine, and macrophages, but also in heart, kidney, adrenal gland, and lung, and LXRb (NR1H2), expressed ubiquitously (Chen et al, 2005). LXRs reside in the nucleus where they heterodimerize with retinoid X receptor and are bound to cognate LXR response elements (LXREs) in regulatory regions of target genes (Peet et al, 1998).
Less is known regarding the role of LXR in pathological cardiac hypertrophy. LXRs have been implicated in blood pressure control by regulating renin gene expression in vivo (Morello et al, 2005). In blood pressure-independent models, the LXR agonist, T0901317 (T09), attenuated the hypertrophic response to pressure overload in mice (Kuipers et al, 2010), whereas this effect was exacerbated in LXRa-null mice (Wu et al, 2009). These studies, however, are limited by confounding systemic effects of pharmacological LXR activation and by the lack of agonist specificity. Therefore, it remains unclear whether LXRa directly affects the pathogenesis of hypertrophy. The purpose of the present study was to investigate the cardiospecificity of LXRa in modulation of myocardial metabolism and pathological hypertrophy by generating a murine model of cardiac-specific LXRa overexpression.

Results
Mice with cardiac-specific LXRa overexpression exhibit no overt cardiac phenotype at baseline or with aging To study LXRa activation in the heart, we generated transgenic (LXRa-Tg) mice with cardiac-specific overexpression of murine LXRa driven by the cardiomyocyte-specific aMHC promoter ( Fig 1A). LXRa mRNA and protein expression were increased 130-fold and 9-fold, respectively (Fig 1B,C and D). Heart weight in LXRa-Tg mice, as assessed by LV weight normalized to tibia length (LV/tibia), was marginally less compared to Wt ( Fig 1E). Mean arterial pressure (MAP) was unaltered in LXRa-Tg mice ( Fig 1F). Echocardiography-determined LV dimensions and function were comparable to Wt, and no differences in indices of contractility and intracardiac pressures, measured in situ with microtip catheterization, were observed (Supplementary Table S1). Histological analyses of ventricular sections stained with WGA-FITC or Masson's trichrome displayed no evidence of abnormal cardiomyocyte morphology or collagen deposition in LXRa-Tg hearts ( Fig 1G). To verify whether overexpression indeed induced functionally active LXRa, we determined mRNA levels of well-described LXRa target genes  including Srebp1c, Scd1, and Abca1. These were significantly increased in LXRa-Tg mice ( Fig 1H). Furthermore, Pgc1a, a co-activator of LXR (Oberkofler et al, 2003), was also upregulated, plausibly to maintain LXRa in a constitutively active state. Lxrb expression was not changed. The long-term effects of cardiac-specific LXRa activation were also assessed in mice up to 12 months of age. Chronic LXRa activation did not impair gross cardiac morphology or function in aged mice (Supplementary  Table S1). In summary, LXRa-Tg mice displayed normal physiological development, and all structural and functional cardiac parameters were within normal range.

LXRa overexpression attenuates pathological development of cardiac hypertrophy, fibrosis, and dysfunction
To evaluate specific effects of LXRa in pathological cardiac hypertrophy, mice were subjected to pressure overload by TAC for 5 weeks. Heart weights were similar between sham-operated Wt and LXRa-Tg groups (Fig 2A). TAC caused significant increases in LV/tibia ratios; however, LXRa-Tg mice exhibited 24% less hypertrophy compared to Wt, which was further evidenced by reduced cardiomyocyte size (Fig 2B and C). In comparison with LXRa-Tg mice, the greater degree of hypertrophy observed in Wt was attributable to larger increases in interventricular septal and LV free wall thicknesses, while no marked dilatation of the LV chamber was observed for either TAC group (Supplementary Table S2). To further assess the impact of LXRa on other parameters of myocardial remodeling, fibrosis was quantified in cross-sectional LV. Collagen deposition was only marginally detected in LXRa-Tg hearts following TAC, whereas this increased 4-fold in Wt (Fig 2C and D). These anti-fibrotic effects were associated with less induction of genes involved in fibrogenesis, Col1a1 and Ctgf ( Fig 2E). Following TAC, typical reactivation of the fetal gene program occurred in both groups, but to a lesser extent in LXRa-Tg mice ( Fig 2E). Interestingly, we observed elevated basal levels of natriuretic peptides, Anp and Bnp, in LXRa-Tg mice. In contrast, other gene markers representative of fetal gene activation were more strongly induced in Wt following TAC: aMHC to bMHC isoform transition (Myh6/Myh7 ratio), Acta1, as well as the hypertrophic gene, Rcan1.
Functional evaluation revealed that Wt mice subjected to TAC achieved significantly less systolic LV thickening and demonstrated greater acceleration toward heart failure as fractional shortening declined 11% versus only 6% in LXRa-Tg ( Fig 3A). These functional improvements in LXRa-Tg mice were further accompanied by reduced intracardiac pressures (Fig 3C and D). No changes in MAP or HR were recorded (Fig 3B, Supplementary  Table S2).
To determine whether cardiac LXRa overexpression affects early hypertrophic remodeling processes, mice were subjected to 1 week of TAC-induced pressure overload. Cardiac hypertrophy was present in Wt mice after 1 week of TAC; however, this was significantly attenuated in LXRa-Tg mice ( Supplementary Fig S1A). Assessment of cardiac function with echocardiography indicated that function remained relatively compensated in TAC-operated mice (Supplementary Fig S1B). The effect of cardiac LXRa on hypertrophy, including expression of fetal genes ( Supplementary Fig S1C), is comparable to what we observed in TAC after 5 weeks. Molecular determinants of inflammation were more strongly upregulated in Wt hearts compared to LXRa-Tg ( Supplementary Fig S1D-G), whereas the anti-apoptotic factor, Bcl2, was significantly induced with LXRa overexpression ( Supplementary Fig S1I and J). These data implicate an anti-inflammatory role for LXRa in the initial phase of hypertrophic pathogenesis, and possible protection against anti-apoptotic triggers.
To further verify that our observations were not model dependent, we conducted experiments with Ang II infusion over 10 days. Consistent with our findings from TAC experiments, LXRa-Tg mice showed reduced Ang II-induced myocardial hypertrophy and fibrosis with moderate improvements in hemodynamic parameters ( Supplementary Fig S2). Taken together, these data demonstrate EMBO Molecular Medicine Vol 7 | No 9 | 2015 ª 2015 The Authors that cardiac-specific LXRa activation ameliorates adverse cardiac remodeling and dysfunction in mice in response to diverse pathological hypertrophic stimuli.

LXRa overexpression induces transcriptional alterations in metabolic pathways
Gene profiling of the LV transcriptome was performed to uncover the molecular basis for the cardioprotective phenotype observed in  Table S3). Basal LXRa overexpression induced substantial changes in genes relating to metabolism ( Fig 4A). To further investigate microarray pathway analysis, mRNA levels of several key genes regulating FA and glucose metabolism were determined (Supplementary Fig S4).
Data information: Data are means AE SEM; one-way ANOVA with Bonferroni's multiple comparison test was used to compare groups.
EMBO Molecular Medicine Vol 7 | No 9 | 2015 ª 2015 The Authors metabolic pathways, for example, glutathione metabolism. Collectively, these expression data convey that LXRa activation transcriptionally reprograms metabolic pathways in the heart, specifically glucose metabolism.

Constitutive LXRa activation enhances myocardial glucose uptake and utilization
We next evaluated whether global transcriptional changes relating to glucose metabolism translated into a functional metabolic outcome. To this end, in vivo glucose uptake measurements were performed in a separate sham/TAC cohort (n = 22) by injecting mice with FDG and using microPET imaging modality. Basal myocardial FDG-glucose uptake was 1.9-fold higher in LXRa-Tg mice compared to Wt, indicating a greater propensity for glucose utilization. Consistent with previous reports showing a substrate shift to glucose following hypertrophic perturbation (Liao et al, 2002;Voelkl et al, 2012), TAC lead to a substantial increase in FDG-glucose uptake in both groups. Wt mice achieved 90% increase, which subsequently matched basal LXRa-Tg levels. On the other hand, TAC-operated LXRa-Tg mice exhibited comparatively even greater capacity for glucose uptake that was augmented 50% above both basal LXRa-Tg levels and that of Wt TAC cohorts (Fig 4B and C). Increased glucose uptake in LXRa-Tg hearts did not impact systemic blood glucose levels as no significant differences in basal levels prior to scan, nor under fasted conditions (Supplementary Table S1), were observed. Furthermore, enhanced glucose uptake was not stored, but rather utilized since myocardial glycogen content was unaltered ( Fig 4D). Expression levels of several key proteins involved in substrate metabolism and regulation were measured. In concert with FDGglucose uptake levels, GLUT1 and GLUT4 protein levels were increased in LXRa-Tg hearts (Fig 4E), suggesting their membrane translocation and functionality. No appreciable differences between LXRa-Tg and Wt were observed for hexokinase 2 (HK2), the enzyme catalyzing the first step in glycolysis, nor phosphorylated-AMPK, a key metabolic regulator in response to increased workload and energetic stress, as well as for CD36 regulating myocardial FA uptake (Supplementary Fig S5). In summary, enhanced myocardial glucose uptake evidenced in LXRa-Tg mice in the stressed and non-stressed state is associated with induction of GLUT1 and GLUT4.
LXRa-deficient mice manifest reduced myocardial glucose uptake capacity in response to TAC To gain further insight into LXRa regulation of myocardial metabolism in cardiac hypertrophy, loss-of-function studies were performed in LXRa À/À mice (Supplementary Table S4). Following 5 weeks of pressure overload, both WT and LXRa À/À mice developed LV hypertrophy ( Fig 5A). The relative increases in LV/tibia ratios were considerably higher for LXRa À/À compared to WT, 50% versus 30%, albeit not significantly different from each other. Furthermore, LXRa-deficient hearts exhibited a greater tendency toward cardiac dysfunction (Fig 5B and C). Activation of the fetal gene program occurred to a similar extent in both LXRa À/À and WT mice (Fig 5D-G).
The metabolic response of LXRa-null hearts to hypertrophic perturbation was assessed by evaluating myocardial glucose uptake and GLUT expression. Both GLUT1 and GLUT4 were evidently less upregulated in LXRa À/À hearts in response to TAC ( Fig 5H). Furthermore, FDG-glucose analysis with microPET revealed that LXRa À/À mice demonstrated an inability to normalize the increases in glucose uptake levels achieved in pressure overload-induced hypertrophy (Fig 5I and J, Supplementary Fig S6). Myocardial glucose uptake increased 1.6-fold in WT, but only 1.3-fold in LXRa À/À mice. Overall, loss of LXRa resulted in a more progressive deterioration of function following TAC that was associated with a compromised adaptive capacity to augment glucose uptake.

Mitochondrial oxidative capacity of pyruvate is unaltered by chronic LXRa overexpression
To assess whether LXRa-Tg mice displayed increased mitochondrial capacity to oxidize glucose-derived substrates, we determined oxidative phosphorylation in permeabilized LV muscle fibers in the presence of pyruvate in an additional sham/TAC cohort (n = 26). Basal (state 2) and maximal ADP-stimulated (state 3) oxygen consumption rates did not differ among stressed and unstressed LXRa-Tg and Wt hearts ( Supplementary Fig S7A), indicating that the capacity for pyruvate oxidation was neither impaired nor enhanced by LXRa overexpression or by TAC. Citrate synthase activity, a marker of mitochondrial density to which all   Fig S7B). Interestingly, we recorded increased state 2 and state 3 respiration rates with palmitoyl (C16)-carnitine in LXRa-Tg, suggesting a trend toward increased capacity to oxidize FA (Supplementary Fig  S7C). This may be due to a reciprocal effect on pyruvate oxidation by Pdk4, which was induced in LXRa-Tg (Supplementary Fig S4A). The respiratory control ratio, indicative of overall mitochondrial function (Brand & Nicholls, 2011), tended to be higher for palmitoylcarnitine in stressed and unstressed hearts overexpressing LXRa (Supplementary Fig S7D). Further lipid profiling revealed increased myocardial leanness in LXRa-Tg hearts ( Supplementary Fig S8), despite induction of several lipogenic gene targets (Srebp1c, Scd1, Fasn) (Fig 1H, Supplementary Fig S4B).

LXRa-mediated glucose uptake increases O-GlcNAc signaling in cardiomyocytes
Since no differences in mitochondrial capacity to utilize pyruvate was identified, we postulated that beneficial effects derived from A LV/tibia ratios in sham-and TAC-operated WT and LXRa À/À mice; n = 10 WT sham, n = 8 LXRa À/À sham, n = 12 WT TAC, n = 10 LXRa À/À TAC. *P = 0.006 versus WT sham, **P = 0.00008 versus LXRa À/À sham. B, C Cardiac functional assessment at 5 weeks post-TAC. (B) Percent fractional shortening determined with echocardiography; n = 10 WT sham, n = 7 LXRa À/À sham, n = 12 WT TAC, n = 10 LXRa À/À TAC. *P < 0.00001 versus respective sham, § P = 0.06. (C) LV end-diastolic pressure (LVEDP) recorded in situ; n = 10 WT sham, n = 7 LXRa À/À sham, n = 10 WT TAC, n = 9 LXRa À/À TAC. *P = 0.001 versus WT sham, **P = 0.00005 versus LXRa À/À sham. D-G Relative mRNA gene expression as determined by RT-PCR, normalized to 36b4; n = 8/group. Anp: no significant differences; Bnp: *P = 0.01 versus WT sham, **P = 0.03 versus LXRa À/À sham; Myh6/Myh7: *P = 0.0002 versus WT sham, **P = 0.0003 versus LXRa À/À sham; Acta1: *P = 0.001 versus respective sham. H Western blot detection of GLUT protein expression in LV tissue normalized to GAPDH, expressed as fold change, shows no significant differences among groups; n = 6-8/group. LXRa-mediated enhanced glucose uptake involved alternate pathways of glycolytic metabolism. One such pathway is the hexosamine biosynthesis pathway (HBP) which culminates in the formation of O-GlcNAc, a posttranslational modifier of numerous proteins. The HBP has been demonstrated to be an essential signaling system in the failing heart (Watson et al, 2010), and accumulating evidence from in vitro and ex vivo systems shows that augmented O-GlcNAc levels via the HBP potentiates cytoprotection Darley-Usmar et al, 2012). Using NRVMs, we tested the hypothesis that LXRa-mediated increases in glucose uptake would enhance substrate availability for O-GlcNAc. NRVMs transfected with Ad-LXRa showed significantly elevated 2-deoxyglucose (2-DG) levels of 1.8-fold compared to Ad-cont cells, which was further augmented 40% following PE stimulation (Fig 6A). Glut4 and Glut1 mRNA levels were correspondingly increased (Fig 6B and  C). Next, we assessed whether enhanced glucose availability led to HBP activation and downstream formation of O-GlcNAc. Ad-LXRa cells displayed increased global protein O-GlcNAcylation that was further enhanced with PE ( Fig 6D). Administration of DON to inhibit HBP flux attenuated Ad-LXRa-increased O-GlcNAcylation ( Fig 6D), confirming the link between LXRa and HBP-O-GlcNAc signaling. From our findings in LXRa-Tg mice, we speculated that increased myocardial natriuretic peptide expression (Fig 2E) in conjunction with preference for glucose may, in part, be evidence of an endogenous cardioprotective stress response elicited via LXRa overexpression. The anti-hypertrophic properties of ANP and BNP are well established (Nishikimi et al, 2006). Ad-LXRa cells expressed both increased Anp and Bnp (3.2-fold and 3.8-fold, respectively), which were subsequently suppressed following DON inhibition, suggesting that their induction is linked to O-GlcNAc effector signaling (Fig 6E  and F). Further assessment of cellular hypertrophy indicated that DON inhibition of HBP flux also abolished the Ad-LXRa-mediated reductions in cell size that was increased upon PE stimulation (Fig 6G and H).
Alternative experiments were performed with si-LXRa to address the causal relationship among LXRa expression, protein O-GlcNAc modification, and hypertrophy. Knockdown of LXRa led to comparatively higher levels of hypertrophic growth (Fig 7A), and lower levels of O-GlcNAc following PE-induced cellular stress (Fig 7B). Interestingly, gene expression analysis (Fig 7C-F) revealed significant downregulation of Anp in LXRa-silenced cells (Fig 7C).

Transcriptional activators of natriuretic peptides are O-GlcNAc modified in LXRa-Tg hearts
Finally, to corroborate our in vitro findings, we assessed global protein O-GlcNAc levels from LV tissue lysates of mice overexpressing and deficient for LXRa. Most extensive O-GlcNAcylation was observed in LXRa-Tg hearts involving proteins between 40 and 55 kDa in size (marked in Fig 8A). In contrast, loss of LXRa resulted in attenuated O-GlcNAc signal in response to TAC (Fig 8B). To further identify specific O-GlcNAc targets, agarose wheat germ agglutinin (WGA) precipitation was performed to isolate nuclear GlcNAcylated proteins. Using antibodies specific for known transcription factors activating ANP and BNP (Morin et al, 2000;Hayek & Nemer, 2011), Western blot analysis revealed that GATA4 and Mef2c precipitated with WGA in LXRa-Tg hearts, but not with Nkx-2.5, suggesting that O-GlcNAc modification of GATA4 and Mef2c potentiates their activities (Fig 8C and D). N-acetylglucosamine (GlcNAc), a competitor, served as a control.
In summary, these data indicate that cardiac LXRa integrates glucose metabolism and downstream O-GlcNAcylation with induction of cytoprotective natriuretic peptides to orchestrate an antihypertrophic response. Therefore, the energy-independent effects of glucose that, herein, are governed by LXRa may be an important salutary mechanism in modulating and preserving myocyte function (Fig 9).

Discussion
In the present study, we describe a cardiac-specific overexpression model for LXRa in mice, and herewith, elucidate the significance of LXRa in modulating myocardial metabolism in pathological hypertrophy. We established that constitutive LXRa activation in murine hearts substantially diminished LV hypertrophy, adverse cardiac remodeling, and improved overall cardiac function following chronic pressure overload and Ang II stimulation. Using this model, we identified the intrinsic transcriptional regulatory mechanisms LXRa exerts in the heart and in counteracting hypertrophic stress. By principally modulating glucose pathways, LXRa functionally enhanced the capacity for myocardial glucose uptake, which was conversely impaired in hypertrophic hearts deficient for LXRa. Furthermore, increased glucose utilization via an energy-independent pathway resulted in the glycosylation of transcription factors inducing natriuretic peptide expression, which we identified as a putative end effector of LXRa-mediated protective effects in the heart.
The role of LXRa in protection against cardiac pathophysiology is not well established. This has been previously addressed in pharmacological studies using the LXR agonist, T09, and LXRa-null mice (Wu et al, 2009;Kuipers et al, 2010). Conceivably, these approaches are restrained by confounding variables associated with systemic LXR activation, which include lipogenic (Peet et al, 1998), anti-inflammatory (Zelcer & Tontonoz, 2006), and blood pressure lowering (Leik et al, 2007) effects. Moreover, T09 mediates its effects indiscriminately via other nuclear receptors since it is also a co-activator of farnesoid X receptor, pregnane X receptor, and retinoic acid receptor signaling (Houck et al, 2004;Mitro et al, 2007;Kumar et al, 2010). Selectively overexpressing cardiac LXRa in mice circumvented these confounding factors and afforded a system for delineating the heart-specific effects of LXRa. Using two diverse hypertrophic perturbations, we demonstrated that constitutive LXRa activation countervailed pathological growth and remodeling processes in the heart, including blunting the development of myocardial fibrosis, an observation in line with previous studies demonstrating the anti-fibrotic effects of LXRs in kidney (Tachibana et al, 2012) and in liver (Beaven et al, 2011). Cardiac LXRa also appears to influence early remodeling processes since less inflammation in association with decreased hypertrophy occurred at an earlier time point of 1 week post-TAC. LXRa-Tg mice may also be less susceptible to apoptosis, which is underscored by upregulation of Bcl2. Taken together, counteraction of inflammatory signaling and myocyte death may explain the attenuated development of fibrosis remodeling we observed after 5 weeks TAC. In loss-of-function studies, LXRa À/À mice did not develop significantly greater severity of hypertrophy with respect to WT, although function was worsened in LXRa-deficient hearts. This is in contrast to a previous report showing exacerbated hypertrophic response in LXRa À/À mice (Wu et al, 2009). The discrepancy between LXRa overexpression and deficiency cannot be fully explained herein; however, our in vitro data indicate that, at the cellular level, there is a clear effect on hypertrophic growth in cardiomyocytes lacking LXRa, and thus, compensatory mechanisms may be operative in the intact heart. Interestingly, recent evidence from a genome-wide association study (GWAS) of electrocardiographic LV hypertrophy (LVH) found a genetic variant, or SNP, in the LXRa (Nr1h3) locus to be significantly associated with the LVH trait. Furthermore, expression QTL analysis showed a significant correlation between decreased expression of Nr1h3 and increased LVH (P. Van der Harst, unpublished data, 2011), supporting an anti-hypertrophic role for LXRa.
Functionally, gene profiling in our model of cardiac-specific LXRa overexpression identified primary effects for LXRa on metabolic pathways, and further investigation into this metabolic profile revealed that myocardial glucose uptake in association with GLUT expression was significantly increased in LXRa-Tg hearts and in isolated cardiomyocytes. GLUT1 and GLUT4 have previously been elucidated as targets for transcriptional regulation by LXRs in adipose tissue and skeletal muscle (Ross et al, 2002;Dalen et al, 2003;Laffitte et al, 2003;Kase et al, 2005;Griesel et al, 2010). Myocardial glucose uptake capacity was enhanced in LXRa-Tg mice, and more importantly, when challenged with hypertrophic stress, these mice demonstrated an even more robust response versus that of Wt. Conversely, insufficient glucose uptake capacity that ensued in hypertrophic hearts deficient for LXRa resulted in a worsened functional outcome. The shift toward greater glucose reliance is believed to be an adaptive response that confers cardioprotection (Opie & Knuuti, 2009;Kolwicz & Tian, 2011), and evidence from other genetic mouse models renders further support for a role for glucose uptake in myocardial protection. Cardiac-specific overexpression of GLUT1 in mice increased glucose uptake and glycolysis which prevented the development of ventricular dysfunction and improved survival (Liao et al, 2002;Luptak et al, 2005), whereas reduced glucose utilization in GLUT4 knockout mice manifested greater hypertrophy and acceleration toward heart failure (Katz et al, . With cardiac insulin resistance and metabolic dysregulation known to precede the development of heart failure (Witteles & Fowler, 2008;Brouwers et al, 2013), strategies sensitizing the heart to glucose uptake may thus have clinically relevant implications in the long-term prognosis of heart failure. Since glucose uptake rates were enhanced by LXRa activation, we hypothesized that this would also lead to downstream changes in energy-dependent pathways, causing increased mitochondrial oxidative capacity. However, we did not observe corresponding increases in oxidative capacity from pyruvate, suggesting that LXRa does not transcriptionally reprogram pathways for the enhancement of mitochondrial glucose utilization. In essence, excess glucose uptake and glycolysis appears to be partially uncoupled from mitochondrial oxidation and ATP synthesis in LXRa-Tg hearts, possibly via a regulatory effect of LXRa on Pdk4, which negatively regulates pyruvate dehydrogenase complex (PDC) activity. This is in contrast to previous reports showing that, in the protection against cardiac stress, GLUT1 overexpression corrected insufficient glucose utilization and oxidation caused by PPARa deficiency in mice (Luptak et al, 2005), and preserved mitochondrial energetic status (Liao et al, 2002). That glucose oxidative capacity is not increased in LXRa-Tg hearts may be due to the fact that mitochondrial oxidation rates are indeed normal and not compromised, and since myocardial contractility is unimpaired is evidence that ATP supply is sufficient to fuel contraction. Consequently, excess glucose uptake is neither stored nor oxidized, but is instead diverted into other glycolytic functions due to a modulatory effect of Pdk4.
Currently, the role of glucose signaling independent of its energyproviding effects is largely unaddressed in the hypertrophic and failing heart, but has been implicated to play an important role in myocyte function and survival (Kolwicz et al, 2013). Moreover, the fate of glucose is of interest given that increased glucose uptake and glycolysis in cardiac hypertrophy do not always result in concomitant increases in glucose oxidation (Allard et al, 1994;Wambolt et al, 1999;Doenst et al, 2013). Our data indicate that, by enhancing glucose flux, cardiac LXRa activates an ancillary pathway of glycolysis, the HBP, increasing levels of the posttranslational modifier, O-GlcNAc. Further, we establish that this pathway induces transcription of natriuretic peptides via glycosylation of GATA4 and Mef2c, transcriptional activators of ANP and BNP (Morin et al, 2000). It is interesting that LXRa-Tg hearts exhibit increased basal ANP and BNP mRNA levels without inducing the complete fetal gene response or displaying signs of cardiac dysfunction normally associated with their induction, suggesting that the expression of individual fetal genes is indeed regulated by distinct signal mechanisms. Nevertheless, the cardioprotective effects of natriuretic peptide signaling are well established (Nishikimi et al, 2006), and murine models with ablated natriuretic peptide signaling show increased propensity for cardiac hypertrophy and myocardial fibrosis (Tamura et al, 2000;Holtwick et al, 2003;Wang et al, 2003). Therefore, the anti-hypertrophic and anti-fibrotic potential of local ANP and BNP signaling may largely contribute to the protective phenotype observed in LXRa-Tg mice, an adaptive response mediated via transcriptional control of glucose-O-GlcNAc-dependent signaling by cardiac LXRa. Future studies aimed at elucidating additional O-GlcNAc targets should provide further insight into the link between myocyte metabolism and survival in the diseased heart. In clinical cardiology, progressive cardiac remodeling often transitions into overt symptomatic heart failure, and although several effective treatments have been developed to prevent this transition, there remains a high residual risk. Alterations in myocardial substrate metabolism contribute to this progression; however, no metabolic modulators are part of the guideline-based therapy for heart failure. Promising pharmacological agents such as trimetazidine and perhexiline inhibit FA oxidation and indirectly cause a reciprocal shift to glucose utilization, yet drugs for direct glucose enhancement are not available. Our data indicate that targeting LXRa as a metabolic intervention to increase glucose metabolism profoundly influenced cardiac hypertrophy and remodeling, independent of hemodynamic or neurohormonal effects.
In conclusion, this study demonstrates that LXRa confers heartspecific protective effects in the attenuation of pathological LV hypertrophy and preservation of cardiac function. We identify LXRa as an important cardiac transcriptional regulator that further promotes the adaptive capacity for glucose uptake and utilization in cardiac hypertrophy. Furthermore, this study highlights the underrecognized potential for non-energy-dependent pathways of glycolysis such as the HBP in promoting cytoprotection. New generation LXR agonists with less lipogenic profiles are currently being developed, and we postulate that such agonists may be useful modulators of myocyte metabolism in the prevention of pathological cardiac remodeling and heart failure.

Materials and Methods
For more detailed Methods, see the Supplementary Information.

Animal models
The murine NR1H3 gene (GeneBank: NM_013839) was obtained from German Science Centre for Genomic Research (RZPD; clone # IRAVp968B0923D). This PCR product was amplified by polymerase chain reaction (PCR) and cloned into a previously described vector containing the cardiac-specific aMHC promoter (Gulick et al, 1991). Transgenic founders were obtained by pronuclear injection of the aMHC-LXRa construct into FVB oocytes. Transgene identification was performed by a PCR-based method using the following primers: sense 5 0 -CGGCACTCTTAGCAAACCTC-3 0 , antisense 5 0 -TGCTGACTC CAACCCTATCC-3 0 . Mice were backcrossed for at least three generations into the C57BL/6 (#000664, The Jackson Laboratory) genetic background. aMHC-LXRa (LXRa-Tg) mice were generated by the UMCG mouse clinic in collaboration with the Mayo Clinic (Rochester, NY, USA). For all experiments, non-transgenic littermates (Wt) served as controls.

Experimental protocol
All experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of Groningen. Male mice (8-10 weeks) were subjected to an infusion of angiotensin II (Ang II) (1.0 mg/kg/day) for 10 days, or pressure overload by transverse aortic constriction (TAC) for either 1 or 5 weeks. In subsequent studies, a subset of mice underwent sham/TAC for 5 weeks for further assessment of myocardial 2-deoxy-2-( 18 F)fluoro-D-glucose (FDG)-glucose uptake with microPET, or mitochondrial oxidative phosphorylation measurements. Cardiac function was determined with echocardiography and invasive hemodynamic monitoring, as previously described (Yu et al, 2013). LV tissue samples were used to perform expressional studies, immunohistochemical, and biochemical analyses.

Statistical analysis
All data are presented as means AE standard error of the mean (SEM). Student's paired 2-tailed t-test was used for two group comparisons. One-way ANOVA was performed to analyze differences for multiple-group comparisons, followed by Bonferroni post hoc analysis. Kruskal-Wallis test followed by Mann-Whitney U-test was used to analyze cell experiments. All results were tested at the P < 0.05 level of significance. The paper explained

Problem
The heart responds to pathological stress by shifting myocardial substrate metabolism toward a greater reliance on glucose. Liver X receptors (LXRs) are nuclear receptors with described functions in lipid and glucose metabolism. Although it has been suggested that pharmacological LXR activation may protect the heart, lipogenic side effects of current LXR agonists preclude their clinical applicability, while the heart-specific effects of LXRs in cardiac pathophysiology and metabolism remain unknown.

Results
Here, we show that LXRa protects the heart from pathological cardiac remodeling. Using a transgenic approach to selectively overexpress LXRa in murine hearts, we demonstrate that the cardioprotective effects of LXRa are indeed heart specific in the attenuation of cardiac hypertrophy and myocardial fibrosis. LXRa overexpression markedly improved cardiac function, as assessed by echocardiography and invasive hemodynamics. Gene profiling revealed that LXRa transcriptionally reprograms metabolic pathways by upregulating a set of genes involved in glucose metabolism. This was functionally confirmed in isolated cardiomyocytes and in vivo with FDG-microPET scanning as LXRa overexpression markedly enhanced the capacity for glucose uptake in response to hypertrophic stress. Conversely, LXRa-deficient mice displayed an impaired adaptive capacity in augmenting glucose uptake. Further, cardiac LXRa overexpression promoted energy-independent utilization of glucose by activating the hexosamine biosynthesis pathway, resulting in downstream O-GlcNAc modification of transcription factors inducing natriuretic peptide expression, a putative end effector of LXRa-mediated anti-hypertrophic effects in the heart.

Impact
We identified LXRa to be a key cardiac transcriptional regulator that mediates an adaptive metabolic response to pathological cardiac stress. Targeting of LXRs as a metabolic intervention in cardiac hypertrophy and heart failure may therefore represent a promising therapeutic approach.